{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T22:29:42Z","timestamp":1788647382642,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Low CD4+ cell count in patients with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) coinfection during combination antiretroviral therapy (cART) has been described; however, notably few studies have investigated coinfected patients positive for antibodies to the HBV c antigen (HBcAb). An observational retrospective study enrolling 190 patients was conducted by grouping patients with respect to HBV status and recording CD4+ T cell counts and percentages (CD4%), CD8+ T cell counts and percentages (CD8%), and the CD4+ to CD8+ T cell ratio (CD4\/CD8) at the time of HIV diagnosis, at the start of treatment and at months 1, 2, 3, 4, 5, 6, 12, and 24 after beginning cART. One hundred and twenty patients (63.2%) were negative for previous HBV infection, while 70 (36.8%) were HBcAb-positive. A significant increase in the CD4\/CD8 ratio was recorded in HIV monoinfected subjects compared to HBV coinfected patients from months 4 to 12 from the beginning of cART (<jats:italic>p<\/jats:italic> value\u2009=\u20090.02 at month 4, <jats:italic>p<\/jats:italic> value\u2009=\u20090.005 at month 5, <jats:italic>p<\/jats:italic> value\u2009=\u20090.006 at month 6, and <jats:italic>p<\/jats:italic> value\u2009=\u20090.008 at month 12). A significant increase in the absolute count of CD8+ T lymphocytes was described from months 2 to 24 from the start of cART in the subgroup of HBV coinfected patients with an AIDS event at the onset of HIV infection. The presence of HBcAb was observed to be associated with reduced CD4\/CD8 ratio growth and a significantly higher proportion of subjects with CD4\/CD8\u2009&lt;\u20090.45 in the HIV\/HBV coinfected group. A significant increase in the CD8 T cell count was shown up to 24\u00a0months after the initiation of effective cART in the subgroup of patients with the worst immune status.<\/jats:p>","DOI":"10.1038\/s41598-021-83616-z","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T16:46:37Z","timestamp":1613753197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Poor CD4\/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers"],"prefix":"10.1038","volume":"11","author":[{"given":"Vincenzo","family":"Malagnino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Cerva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Teti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Campogiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Compagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Foroghi Biland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Saderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Armenia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Salpini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Svicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Sotgiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Iannetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Andreoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Sarmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"83616_CR1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/cid\/cis432","volume":"55","author":"O Falade-Nwulia","year":"2012","unstructured":"Falade-Nwulia, O. et al. Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection. Clin. Infect. Dis. 55, 507\u2013513 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"83616_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/cid\/cix747","volume":"66","author":"G-M Kouam\u00e9","year":"2018","unstructured":"Kouam\u00e9, G.-M. et al. Higher mortality despite early antiretroviral therapy in human immunodeficiency virus and hepatitis B virus (HBV)-coinfected patients with high HBV replication. Clin. Infect. Dis. 66, 112\u2013120 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"83616_CR3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/00002030-199206000-00008","volume":"6","author":"A Eskild","year":"1992","unstructured":"Eskild, A. et al. Hepatitis B antibodies in HIV-infected homosexual men are associated with more rapid progression to AIDS. AIDS 6, 571\u2013574 (1992).","journal-title":"AIDS"},{"key":"83616_CR4","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1097\/QAD.0b013e328355ced2","volume":"26","author":"H Wang","year":"2012","unstructured":"Wang, H. et al. Immunological and virological responses to cART in HIV\/HBV co-infected patients from a multicenter cohort. AIDS 26, 1755\u20131763 (2012).","journal-title":"AIDS"},{"issue":"15","key":"83616_CR5","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1097\/QAD.0000000000001574","volume":"31","author":"KP Singh","year":"2017","unstructured":"Singh, K. P. et al. HIV hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS. 31(15), 2035\u20132052 (2017).","journal-title":"AIDS."},{"issue":"2","key":"83616_CR6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s11904-018-0379-y","volume":"15","author":"JJ Chang","year":"2018","unstructured":"Chang, J. J., Mohtashemi, N. & Bhattacharya, D. Significance and management of isolated hepatitis B core antibody (anti-HBc) in HIV and HCV: strategies in the DAA era. Curr. HIV\/AIDS Rep. 15(2), 172\u2013181 (2018).","journal-title":"Curr. HIV\/AIDS Rep."},{"issue":"2","key":"83616_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4254\/wjh.v7.i2.253","volume":"7","author":"A Maldonado-Rodriguez","year":"2015","unstructured":"Maldonado-Rodriguez, A. et al. Occult hepatitis B virus co-infection in human immunodeficiency virus-positive patients: a review of prevalence, diagnosis and clinical significance. World J. Hepatol. 7(2), 253\u2013260 (2015).","journal-title":"World J. Hepatol."},{"issue":"2","key":"83616_CR8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1478-3231.2011.02481.x","volume":"32","author":"Y Shi","year":"2012","unstructured":"Shi, Y. et al. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis: association between occult HBV infection and the risk of HCC. Liver Int. 32(2), 231\u2013240 (2012).","journal-title":"Liver Int."},{"issue":"3","key":"83616_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/jvh.12222","volume":"21","author":"X Huang","year":"2014","unstructured":"Huang, X. & Hollinger, F. B. Occult hepatitis B virus infection and hepatocellular carcinoma: a systematic review. J. Viral Hepat. 21(3), 153\u2013162 (2014).","journal-title":"J. Viral Hepat."},{"issue":"3","key":"83616_CR10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/jmv.21422","volume":"81","author":"JWT Cohen Stuart","year":"2009","unstructured":"Cohen Stuart, J. W. T., Velema, M. & Schuurman, R. B 425 oucher CAB, Hoepelman AIM: occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J. Med. Virol. 81(3), 441\u2013445 (2009).","journal-title":"J. Med. Virol."},{"key":"83616_CR11","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/infdis\/jit351","volume":"208","author":"G Wandeler","year":"2013","unstructured":"Wandeler, G. et al. Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study. J. Infect. Dis. 208, 1454\u20131458 (2013).","journal-title":"J. Infect. Dis."},{"issue":"3","key":"83616_CR12","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/jmv.21422","volume":"81","author":"JWT Cohen Stuart","year":"2009","unstructured":"Cohen Stuart, J. W. T., Velema, M., Schuurman, R., Boucher, C. A. B. & Hoepelman, A. I. M. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J. Med. Virol. 81(3), 441\u2013445 (2009).","journal-title":"J. Med. Virol."},{"key":"83616_CR13","doi-asserted-by":"publisher","first-page":"ofw140","DOI":"10.1093\/ofid\/ofw140","volume":"3","author":"M Anderson","year":"2016","unstructured":"Anderson, M. et al. Slow CD4+ T-cell recovery in human immunodeficiency virus\/hepatitis b virus-coinfected patients initiating truvada-based combination antiretroviral therapy in Botswana. Open Forum Infect. Dis. 3, ofw140 (2016).","journal-title":"Open Forum Infect. Dis."},{"key":"83616_CR14","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/0006-291X(75)90506-9","volume":"66","author":"UN Wiesmann","year":"1975","unstructured":"Wiesmann, U. N., DiDonato, S. & Herschkowitz, N. N. Effect of chloroquine on cultured fibroblasts: release of lysosomal hydrolases and inhibition of their uptake. Biochem. Biophys. Res. Commun. 66, 1338\u20131343 (1975).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"83616_CR15","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1093\/cid\/cit002","volume":"56","author":"GV Matthews","year":"2013","unstructured":"Matthews, G. V. et al. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. Clin. Infect. Dis. 56, e87-94 (2013).","journal-title":"Clin. Infect. Dis."},{"key":"83616_CR16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/hep.27182","volume":"60","author":"A Boyd","year":"2014","unstructured":"Boyd, A. et al. Persistent viremia in human immunodeficiency virus\/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications. Hepatology 60, 497\u2013507 (2014).","journal-title":"Hepatology"},{"key":"83616_CR17","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1086\/593104","volume":"47","author":"CJ Hoffmann","year":"2008","unstructured":"Hoffmann, C. J. et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin. Infect. Dis. 47, 1479\u20131485 (2008).","journal-title":"Clin. Infect. Dis."},{"key":"83616_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/01.aids.0000163936.99401.fe","volume":"19","author":"D Konopnicki","year":"2005","unstructured":"Konopnicki, D. et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 19, 593\u2013601 (2005).","journal-title":"AIDS"},{"key":"83616_CR19","doi-asserted-by":"publisher","first-page":"11942","DOI":"10.1038\/s41598-019-46976-1","volume":"9","author":"V Malagnino","year":"2019","unstructured":"Malagnino, V. et al. HBcAbseropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV\/HBV-coinfected patients on first-line therapy. Sci. Rep. Value 9, 11942 (2019).","journal-title":"Sci. Rep. Value"},{"key":"83616_CR20","unstructured":"Italian Guidelines on the use of Antiretroviral Therapy and the diagnostic-clinical management of people with HIV-1 infection. Edition 2017. http:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_2696_allegato.pdf. Accessed 26 August 2020"},{"key":"83616_CR21","unstructured":"WHO. Antiretroviral therapy for HIV infection in adults and adolescents, recommendations for a public health approach 2010 revision. Available: https:\/\/www.int\/entity\/hiv\/pub\/arv\/adult2010\/en\/index.html. Accessed 2012 July 25 (2010)."},{"key":"83616_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1086\/504718","volume":"194","author":"M Goicoechea","year":"2006","unstructured":"Goicoechea, M. et al. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J. Infect. Dis. 194, 29\u201337 (2006).","journal-title":"J. Infect. Dis."},{"key":"83616_CR23","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/S0140-6736(02)11913-1","volume":"360","author":"CL Thio","year":"2002","unstructured":"Thio, C. L. et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the multicenter cohort study (MACS). Lancet 360, 1921\u20131926 (2002).","journal-title":"Lancet"},{"key":"83616_CR24","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1086\/522173","volume":"45","author":"W-H Sheng","year":"2007","unstructured":"Sheng, W.-H. et al. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin. Infect. Dis. 45, 1221\u20131229 (2007).","journal-title":"Clin. Infect. Dis."},{"key":"83616_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/infdis\/jir720","volume":"205","author":"HM Chun","year":"2012","unstructured":"Chun, H. M. et al. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J. Infect. Dis. 205, 185\u2013193 (2012).","journal-title":"J. Infect. Dis."},{"key":"83616_CR26","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1093\/infdis\/jit299","volume":"208","author":"M-S Tsai","year":"2013","unstructured":"Tsai, M.-S. et al. Hepatitis B virus (HBV) coinfection accelerates immunologic progression in patients with primary HIV infection in an area of hyperendemicity for HBV infection. J. Infect. Dis. 208, 1184\u20131186 (2013).","journal-title":"J. Infect. Dis."},{"key":"83616_CR27","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1086\/520989","volume":"45","author":"JI Tsui","year":"2007","unstructured":"Tsui, J. I. et al. Prevalence and long-term effects of occult hepatitis B virus infection in HIV-infected women. Clin. Infect. Dis. 45, 736\u2013740 (2007).","journal-title":"Clin. Infect. Dis."},{"key":"83616_CR28","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s11904-018-0379-y","volume":"15","author":"JJ Chang","year":"2018","unstructured":"Chang, J. J., Mohtashemi, N. & Bhattacharya, D. Significance and management of isolated hepatitis B core antibody (Anti-HBc) in HIV and HCV: strategies in the DAA era. Curr. HIV\/AIDS Rep. Value 15, 172\u2013181 (2018).","journal-title":"Curr. HIV\/AIDS Rep. Value"},{"issue":"2","key":"83616_CR29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jhep.2019.03.034","volume":"71","author":"G Raimondo","year":"2019","unstructured":"Raimondo, G. et al. Taormina workshop on occult HBV infection faculty members. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J. Hepatol. 71(2), 397\u2013408 (2019).","journal-title":"J. Hepatol."},{"key":"83616_CR30","unstructured":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv\/whats-new-guidelines. accessed 08 November 2020."},{"issue":"2","key":"83616_CR31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jhep.2018.03.021","volume":"69","author":"GP Caviglia","year":"2018","unstructured":"Caviglia, G. P. et al. Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: a new tool to detect occult infection. J. Hepatol. 69(2), 301\u2013307 (2018).","journal-title":"J. Hepatol."},{"issue":"9","key":"83616_CR32","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3390\/v11090783","volume":"11","author":"V Svicher","year":"2019","unstructured":"Svicher, V. et al. New markers in monitoring the reactivation of hepatitis B virus infection in immunocompromised hosts. Viruses 11(9), 783 (2019).","journal-title":"Viruses"},{"issue":"7","key":"83616_CR33","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.4049\/jimmunol.1502061","volume":"196","author":"D Zhu","year":"2016","unstructured":"Zhu, D. et al. Clearing persistent extracellular antigen of hepatitis B virus: an immunomodulatory strategy to reverse tolerance for an effective therapeutic vaccination. J. Immunol. 196(7), 3079\u20133087 (2016).","journal-title":"J. Immunol."},{"key":"83616_CR34","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/hep.29082","volume":"66","author":"S Paul","year":"2017","unstructured":"Paul, S. et al. Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta-analysis. Hepatology 66, 379\u2013388 (2017).","journal-title":"Hepatology"},{"key":"83616_CR35","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1093\/infdis\/jiu669","volume":"211","author":"M Helleberg","year":"2015","unstructured":"Helleberg, M. et al. Course and clinical significance of CD8+ T-cell counts in a large cohort of HIV-infected individuals. J. Infect. Dis. 211, 1726\u20131734 (2015).","journal-title":"J. Infect. Dis."},{"issue":"1","key":"83616_CR36","doi-asserted-by":"publisher","first-page":"20697","DOI":"10.7448\/IAS.19.1.20697","volume":"19","author":"W Cao","year":"2016","unstructured":"Cao, W., Mehraj, V., Kaufmann, D. E., Li, T. & Routy, J. P. Elevation and persistence of CD8 T-cells in HIV infection: the Achilles heel in the ART era. J. Int. AIDS Soc. 19(1), 20697. https:\/\/doi.org\/10.7448\/IAS.19.1.20697 (2016).","journal-title":"J. Int. AIDS Soc."},{"key":"83616_CR37","doi-asserted-by":"publisher","first-page":"e0173893","DOI":"10.1371\/journal.pone.0173893","volume":"12","author":"F Chereau","year":"2017","unstructured":"Chereau, F. et al. Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. PLoS ONE 12, e0173893 (2017).","journal-title":"PLoS ONE"},{"key":"83616_CR38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1054-139X(01)00278-6","volume":"29","author":"CM Wilson","year":"2001","unstructured":"Wilson, C. M. et al. Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort. J. Adolesc. Health 29, 123\u2013129 (2001).","journal-title":"J. Adolesc. Health"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83616-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83616-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83616-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T03:52:20Z","timestamp":1670039540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83616-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["83616"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-83616-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"22 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare they have no conflicts of interest related to this manuscript. However, MA has received funds for attending symposia, speaking, grant research support, consultancy and advisory board membership from ABBOT, BRISTOL, GILEAD, MERCK, JANSENN CILAG, PFIZER, ROCHE, and ViiV HEALTHCARE. LS has received funds for attending symposia, speaking, and grant research support from GILEAD, MERCK, JANSENN CILAG, PFIZER, and ViiV HEALTHCARE.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3965"}}